You are here: Home » PTI Stories » National » News
Business Standard

Suven Life gets product patents from Israel, Japan

Press Trust of India  |  New Delhi 

Sciences Tuesday said it has been granted a product each by and Japan, for a (NCE) that is used in the treatment of associated with

These patents are valid through 2036 and 2034 respectively, the company said in a BSE filing.

"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the Central (CNS) arena, which are being developed for with high unmet medical need with a huge market potential globally," said.

The granted claims of patents are being developed as therapeutic agents useful in the associated with like Alzheimer's disease, (ADHD), Huntington's disease, and schizophrenia, it added.

Shares of Sciences were trading 0.56 per cent up at Rs 242.10 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, November 06 2018. 11:25 IST